EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Research Progress of Drug Delivery Systems Targeting the Kidneys

Li-Feng Huang, Qiao-Ru Ye, Xiao-Cui Chen, Xiao-Rong Huang, Qiao-Fei Zhang, Chun-Yu Wu, Hua-Feng Liu, Chen Yang

Pharmaceuticals · 13.05.2024 · 17 (5) · 625

DOI: 10.3390/ph17050625 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.05.2024. Verfasst von Li-Feng Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Key Laboratory of Prevention and Management of Chronic …. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) affects more than 10% of the global population, and its incidence is increasing, partially due to an increase in the prevalence of disease risk factors. Acute kidney injury (AKI) is an independent risk factor for CKD and end-stage renal disease (ESRD). The pathogenic mechanisms of CKD provide several potential targets for its treatment. However, due to off-target effects, conventional drugs for CKD typically require high doses to achieve adequate therapeutic effects, leading to long-term organ toxicity. Therefore, ideal treatments that completely cure the different types of kidney disease are rarely available. Several approaches for the drug targeting of the kidneys have been explored in drug delivery system research. Nanotechnology-based drug delivery systems have multiple merits, including good biocompatibility, suitable degradability, the ability to target lesion sites, and fewer non-specific systemic effects. In this review, the development, potential, and limitations of low-molecular-weight protein–lysozymes, polymer nanomaterials, and lipid-based nanocarriers as drug delivery platforms for treating AKI and CKD are summarized.

Schlagwörter

Stichwörter der Autor:innen

acute kidney injurychronic kidney diseaseglomerulusnanotechnologytubule

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases
  • Discipline Construction Project of Guangdong Medical University
  • National Clinical Key Specialty Construction Project (Institute of Nephrology, Affiliated Hospital of Guangdong Medical University)
  • Affiliated Hospital of Guangdong Medical University Clinical Research Program

Zitieren

APA

Huang, L. F., Ye, Q. R., Chen, X. C., Huang, X. R., Zhang, Q. F., Wu, C. Y., Liu, H. F., & Yang, C. (2024). Research Progress of Drug Delivery Systems Targeting the Kidneys. Pharmaceuticals, 17(5), 625. https://doi.org/10.3390/ph17050625

Vancouver

Huang LF, Ye QR, Chen XC, Huang XR, Zhang QF, Wu CY, et al. Research Progress of Drug Delivery Systems Targeting the Kidneys. Pharmaceuticals. 2024;17(5):625. doi:10.3390/ph17050625

BibTeX
@article{Huang2024,
  author = {Huang, Li-Feng and Ye, Qiao-Ru and Chen, Xiao-Cui and Huang, Xiao-Rong and Zhang, Qiao-Fei and Wu, Chun-Yu and Liu, Hua-Feng and Yang, Chen},
  title = {Research Progress of Drug Delivery Systems Targeting the Kidneys},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {5},
  pages = {625},
  doi = {10.3390/ph17050625}
}
Kostenlos starten →